We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antibacterial antibodies gain traction.
- Authors
Morrison, Chris
- Abstract
The article discusses findings of Phase III studies which provide evidence on the efficacy of antibody therapy in the treatment of bacterial infections. It notes that Phase III trials of the antibody bezlotoxumab by pharmaceutical firm Merck & Co. showed a reduction in the recurrence of Clostridium difficile through 12 weeks by inhibiting the bacteria's fatal toxin B. It also mentions ongoing studies to develop antibody therapy targeting the alpha toxin of Staphylococcus aureus bacteria.
- Subjects
ANTIBACTERIAL agents; IMMUNOGLOBULINS; CLINICAL trials; DRUG efficacy; STAPHYLOCOCCUS aureus; ANTIBIOTICS; ANIMALS; BACTERIAL diseases; INDUSTRIES; BACTERIAL antibodies; THERAPEUTICS
- Publication
Nature Reviews Drug Discovery, 2015, Vol 14, Issue 11, p737
- ISSN
1474-1776
- Publication type
journal article
- DOI
10.1038/nrd4770